Biophan outlines technological and financial strategy
5 December 2005
Rochester N.Y. CEO of Biophan Technologies, Inc., Michael Weiner,
addressed a group of Swiss investors at a meeting in Tagerwilen,
Switzerland, in which he provided an overview of the Company's technologies
and strategic initiatives, as well as a five-year outlook for potential
Company revenues from licensing of its proprietary biomedical technologies
and product sales.
Mr. Weiner discussed Biophan's portfolio of technologies for magnetic
resonance image compatibility of medical devices such as stents, vena cava
filters, and interventional devices. If successfully developed and accepted
in the marketplace, these technologies have the potential to generate annual
licensing revenues totaling $100 million or more within approximately five
years, primarily from royalty payments, he said. In addition, he indicated
that licensing revenues related to MRI safety for implantable medical
devices, including pacemakers, implantable cardioverter defibrillators
(ICDs), and neurostimulators have the potential to reach $40 million per
annum within the same five-year time frame. As with any revenue forecast,
these projections are subject to various factors, and there are no
assurances that the Company will successfully commercialize all of these
technologies or achieve these estimated revenue levels.
In addition to these licensing-related forecasts, the Company also
announced potential product sales revenues related to the MYO-VAD cardiac
assist device of up to $100 million per year within the same approximate
five-year period. He added that these projections are dependent upon various
factors including FDA approval of the product line currently in development.
As previously announced, Biophan executed a letter of intent to acquire a
minority interest in MYOTECH, LLC, the developer of the MYO-VAD device, with
rights to acquire a majority interest in exchange for funding the
In subsequent years, additional growth is expected. The Company provided
no additional specific guidance; however, the Company did indicate that it
anticipates that the MYO-VAD product has the potential to achieve
significant market share in the multibillion dollar ventricular assist
"Biophan is very excited by the potential that the MYO-VAD technology
adds to our portfolio of products," said Mr. Weiner. "We anticipate closing
a deal with a distribution partner for the MYO-VAD within 24 months, and
that the partner will bear costs related to clinical trials, marketing, and
"Although we cannot make any definitive statements or guarantees of any
kind regarding Biophan's forward-looking revenue potential, we are excited
by both the medical and market potential that the MYO-VAD technology
represents. It is an important addition to our portfolio of biomedical
innovations for improved cardiac care and for enhanced MRI safety and image
In addition to the established technologies for which Biophan announced
these forecasts, Biophan also continues development of a long-term product
pipeline of technologies such as a novel biothermal power supply and
controlled drug delivery methods. The Company is jointly developing the
biothermal power source with NASA's Ames Research Center. The power supply
is designed to generate power from a patient's natural body heat, and to
replace and/or augment traditional batteries in implanted devices.
The Company is also working to adapt its nanomagnetic particle technology
to produce novel MRI contrast agents and controlled drug delivery materials.
These technologies are still in early development stages, and no forecasts
have been provided related to their commercialization.
Over fifty investors, invited by Capital Management AG, attended the
meeting, including major banks, institutional fund managers, individual
investors, and Capital Management personnel. The meeting was held at Capital
Management's headquarters in Tagerwilen, Switzerland. Biophan is one of the
stocks listed in Capital Management's "Aktientipps" portfolio.
The presentation was given by Michael Weiner, CEO of Biophan, and Dr.
Andreas Melzer, Chief Technology Office or Biophan Europe. Dr. Melzer
presented updated information on the MRI safe and/or image compatible heart
valve, stent, vena cava filter, and implantation catheter, and an overview
of the medical benefits of procedures performed under MRI vs. under X-Ray.
The presentations were given in both English and German.
Mr. Weiner's presentation can be viewed at